MARKET

BLUE

BLUE

bluebird bio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

86.97
+1.28
+1.49%
After Hours: 87.49 +0.52 +0.60% 19:30 12/11 EST
OPEN
86.85
PREV CLOSE
85.69
HIGH
92.05
LOW
86.09
VOLUME
3.29M
TURNOVER
--
52 WEEK HIGH
163.43
52 WEEK LOW
71.42
MARKET CAP
4.81B
P/E (TTM)
-6.6951
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of BLUE and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 21 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

BLUE News

  • bluebird bio (BLUE) Presents At 2019 ASH Annual Meeting - Slideshow
  • Seeking Alpha - Article.13h ago
  • Is bluebird bio Inc (BLUE) Going to Burn These Hedge Funds?
  • Insider Monkey.13h ago
  • Biotech Stock Roundup: ASH Data in Focus, Amgen Gets FDA Nod to Remicade Biosimilar
  • Zacks.16h ago
  • Bluebird bio Is Remarkably Undervalued, Analyst Says
  • Barrons.com.17h ago

More

Industry

Biotechnology & Medical Research
-0.34%
Pharmaceuticals & Medical Research
+0.06%

Hot Stocks

Name
Price
%Change

About BLUE

bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company's clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD). Its programs in oncology focuses on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. bb2121, its lead product candidate in oncology, is a CAR T cell product candidate for the treatment of multiple myeloma. It also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.
More

Webull offers bluebird bio Inc (BLUE) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.